RNA, Messenger – Talk Bio

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

1 week ago talkbio0Tagged Advanced therapies, Alternative, Cells, Clinical Trials, commercialization, Gene Modification, gene therapy, Industry, meeting, MESA, partnerships, payment, Phoenix Arizona, regulatory challenges, RNA, Messenger, Study models

Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

2 months ago talkbio0Tagged BioNTech, BioNTech acquisition, COVID19 (disease), CureVac, global framework, Influenza virus vaccine, Licensing, Litigation, Pfizer, RNA, Messenger, royalties, settlement, SmithKline Beecham, U.S., upfront payment, Vaccines, Vaccines, Combined

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

4 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants

10 months ago talkbio0Tagged Advisory Committees, concerns, Infant, Moderna, Respiratory syncytial virus, RNA, Messenger, Safety, United States Food and Drug Administration, Vaccines

Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee

Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages

12 months ago talkbio0Tagged analytical method, Automation, bony process, clinical transition, Control Groups, Materials, Preclinical, Quality, regulatory, Risk Management, RNA, Messenger

mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.

GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results

1 year ago talkbio0Tagged Clinical Development, Effectiveness, Late stage, RNA, Messenger, Safety, SmithKline Beecham, Vaccines

GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.

GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech

1 year ago talkbio0Tagged BioNTech, HSV vaccine, Moderna, RNA, Messenger, Simplexvirus, SmithKline Beecham

GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus

FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection

1 year ago talkbio0Tagged Approved, authorization, COVID19 (disease), Emergency Situation, Guidelines, JN.1, KP.2, Lineage, Moderna, Pfizer, Pfizer/, RNA, Messenger, United States Food and Drug Administration, Vaccination, Vaccines, Variant

COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.

GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

1 year ago talkbio0Tagged bioplatform companies, Drug Discovery, Flagship, Immunology, Partnership, Pfizer, Pioneering, Respiration Disorders, RNA, Messenger, SmithKline Beecham, Vaccines

GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership

Moderna Secures $176 Million BARDA Award for Bird Flu Vaccine Development

1 year ago talkbio0Tagged BARDA, development aspects, Influenza in Birds, Moderna, pandemic preparedness, RNA, Messenger, Vaccines

Moderna, BARDA, Bird Flu, Vaccine Development, mRNA Technology, Pandemic Preparedness